Withdrawal of familial ovarian cancer screening for surgery:: findings from a psychologicalevaluation study (PsyFOCS)

Deborah Lancastle; Rachel Iredale; Dr Kate Lifford; Lindsay Fraser; Dr Adam Rosenthal; Dr Mark Rogers; Dr Ceri Phelps; Professor Eila Watson; Alison Clements; Professor Ian Jacobs; Professor Usha Menon; Dr Kate Brain

doi:10.1016/j.ygyno.2011.09.015

Withdrawal of familial ovarian cancer screening for surgery: findings from a psychologicalevaluation study (PsyFOCS)

Deborah Lancastle, Rachel Iredale, Dr Kate Lifford, Lindsay Fraser, Dr Adam Rosenthal, Dr Mark Rogers, Dr Ceri Phelps, Professor Eila Watson, Alison Clements, Professor Ian Jacobs, Professor Usha Menon, Dr Kate Brain

Faculty of Life Sciences and Education

Research output: Contribution to journal › Article › peer-review

Abstract

Objective -
A prospective psychological evaluation study of familial ovarian cancer screening (PsyFOCS) is underway in partnership with the UK Familial Ovarian Cancer Screening Study (UK FOCSS Phase 2). One of the aims of PsyFOCS is to examine factors associated with withdrawal from the UK FOCSS prior to the onset of 4-monthly screening.

Method -
1999 of 3224 women completed a baseline questionnaire. 110 (5.5%) women withdrew from screening prior to their first routine Phase 2 screen, of which 73 (66.4% of withdrawals) had withdrawn because they had undergone removal of their ovaries and fallopian tubes (withdrawn group). The comparison group consisted of 1868 women who remained on screening. The baseline questionnaire included measures of cancer-specific distress, anxiety, depression and illness perceptions.

Results -
Logistic regression analysis indicated that having had prior annual (Phase 1) screening (OR=13.34, pb.01), past experience of further tests (OR=2.37, pb.01) and greater cancer-specific distress (OR=1.38, pb.01) were associated with withdrawal for surgery. Belief in ageing as a cause of ovarian cancer was also associated with withdrawal (OR=1.32, p=.05).

Conclusion -
These cross-sectional data suggest that withdrawal from familial ovarian cancer screening may be influenced by both clinical and psychological factors. These may reflect women's experience of the drawbacks of screening and increased concern about ovarian cancer risk, as well as having opportunities to consider surgery as an alternative risk management strategy whilst using screening as an interim measure.

Original language	English
Pages (from-to)	158 - 163
Number of pages	5
Journal	Gynaecologic Oncology
Volume	124
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2011.09.015
Publication status	Published - 1 Jan 2012

Keywords

Ovarian cancer
Ovarian cancer screening
Familial cancer
Withdrawal from screening
Cancer-specific distress
Risk-reducing salpingo-oophorectomy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2011.09.015Licence: CC BY-NC-ND

Cite this

Lancastle, D., Iredale, R., Lifford, D. K., Fraser, L., Rosenthal, D. A., Rogers, D. M., Phelps, D. C., Watson, P. E., Clements, A., Jacobs, P. I., Menon, P. U., & Brain, D. K. (2012). Withdrawal of familial ovarian cancer screening for surgery: findings from a psychologicalevaluation study (PsyFOCS). Gynaecologic Oncology, 124(1), 158 - 163. https://doi.org/10.1016/j.ygyno.2011.09.015

@article{fd3b3c7e703c4751a79356d7f4dcb9a9,

title = "Withdrawal of familial ovarian cancer screening for surgery:: findings from a psychologicalevaluation study (PsyFOCS)",

abstract = "Objective - A prospective psychological evaluation study of familial ovarian cancer screening (PsyFOCS) is underway in partnership with the UK Familial Ovarian Cancer Screening Study (UK FOCSS Phase 2). One of the aims of PsyFOCS is to examine factors associated with withdrawal from the UK FOCSS prior to the onset of 4-monthly screening. Method - 1999 of 3224 women completed a baseline questionnaire. 110 (5.5%) women withdrew from screening prior to their first routine Phase 2 screen, of which 73 (66.4% of withdrawals) had withdrawn because they had undergone removal of their ovaries and fallopian tubes (withdrawn group). The comparison group consisted of 1868 women who remained on screening. The baseline questionnaire included measures of cancer-specific distress, anxiety, depression and illness perceptions. Results - Logistic regression analysis indicated that having had prior annual (Phase 1) screening (OR=13.34, pb.01), past experience of further tests (OR=2.37, pb.01) and greater cancer-specific distress (OR=1.38, pb.01) were associated with withdrawal for surgery. Belief in ageing as a cause of ovarian cancer was also associated with withdrawal (OR=1.32, p=.05). Conclusion - These cross-sectional data suggest that withdrawal from familial ovarian cancer screening may be influenced by both clinical and psychological factors. These may reflect women's experience of the drawbacks of screening and increased concern about ovarian cancer risk, as well as having opportunities to consider surgery as an alternative risk management strategy whilst using screening as an interim measure.",

keywords = "Ovarian cancer, Ovarian cancer screening, Familial cancer, Withdrawal from screening , Cancer-specific distress , Risk-reducing salpingo-oophorectomy",

author = "Deborah Lancastle and Rachel Iredale and Lifford, {Dr Kate} and Lindsay Fraser and Rosenthal, {Dr Adam} and Rogers, {Dr Mark} and Phelps, {Dr Ceri} and Watson, {Professor Eila} and Alison Clements and Jacobs, {Professor Ian} and Menon, {Professor Usha} and Brain, {Dr Kate}",

year = "2012",

month = jan,

day = "1",

doi = "10.1016/j.ygyno.2011.09.015",

language = "English",

volume = "124",

pages = "158 -- 163",

journal = "Gynaecologic Oncology",

issn = "0090-8258",

publisher = "Elsevier",

number = "1",

}

Lancastle, D, Iredale, R, Lifford, DK, Fraser, L, Rosenthal, DA, Rogers, DM, Phelps, DC, Watson, PE, Clements, A, Jacobs, PI, Menon, PU & Brain, DK 2012, 'Withdrawal of familial ovarian cancer screening for surgery: findings from a psychologicalevaluation study (PsyFOCS)', Gynaecologic Oncology, vol. 124, no. 1, pp. 158 - 163. https://doi.org/10.1016/j.ygyno.2011.09.015

TY - JOUR

T1 - Withdrawal of familial ovarian cancer screening for surgery:

T2 - findings from a psychologicalevaluation study (PsyFOCS)

AU - Lancastle, Deborah

AU - Iredale, Rachel

AU - Lifford, Dr Kate

AU - Fraser, Lindsay

AU - Rosenthal, Dr Adam

AU - Rogers, Dr Mark

AU - Phelps, Dr Ceri

AU - Watson, Professor Eila

AU - Clements, Alison

AU - Jacobs, Professor Ian

AU - Menon, Professor Usha

AU - Brain, Dr Kate

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Objective - A prospective psychological evaluation study of familial ovarian cancer screening (PsyFOCS) is underway in partnership with the UK Familial Ovarian Cancer Screening Study (UK FOCSS Phase 2). One of the aims of PsyFOCS is to examine factors associated with withdrawal from the UK FOCSS prior to the onset of 4-monthly screening. Method - 1999 of 3224 women completed a baseline questionnaire. 110 (5.5%) women withdrew from screening prior to their first routine Phase 2 screen, of which 73 (66.4% of withdrawals) had withdrawn because they had undergone removal of their ovaries and fallopian tubes (withdrawn group). The comparison group consisted of 1868 women who remained on screening. The baseline questionnaire included measures of cancer-specific distress, anxiety, depression and illness perceptions. Results - Logistic regression analysis indicated that having had prior annual (Phase 1) screening (OR=13.34, pb.01), past experience of further tests (OR=2.37, pb.01) and greater cancer-specific distress (OR=1.38, pb.01) were associated with withdrawal for surgery. Belief in ageing as a cause of ovarian cancer was also associated with withdrawal (OR=1.32, p=.05). Conclusion - These cross-sectional data suggest that withdrawal from familial ovarian cancer screening may be influenced by both clinical and psychological factors. These may reflect women's experience of the drawbacks of screening and increased concern about ovarian cancer risk, as well as having opportunities to consider surgery as an alternative risk management strategy whilst using screening as an interim measure.

AB - Objective - A prospective psychological evaluation study of familial ovarian cancer screening (PsyFOCS) is underway in partnership with the UK Familial Ovarian Cancer Screening Study (UK FOCSS Phase 2). One of the aims of PsyFOCS is to examine factors associated with withdrawal from the UK FOCSS prior to the onset of 4-monthly screening. Method - 1999 of 3224 women completed a baseline questionnaire. 110 (5.5%) women withdrew from screening prior to their first routine Phase 2 screen, of which 73 (66.4% of withdrawals) had withdrawn because they had undergone removal of their ovaries and fallopian tubes (withdrawn group). The comparison group consisted of 1868 women who remained on screening. The baseline questionnaire included measures of cancer-specific distress, anxiety, depression and illness perceptions. Results - Logistic regression analysis indicated that having had prior annual (Phase 1) screening (OR=13.34, pb.01), past experience of further tests (OR=2.37, pb.01) and greater cancer-specific distress (OR=1.38, pb.01) were associated with withdrawal for surgery. Belief in ageing as a cause of ovarian cancer was also associated with withdrawal (OR=1.32, p=.05). Conclusion - These cross-sectional data suggest that withdrawal from familial ovarian cancer screening may be influenced by both clinical and psychological factors. These may reflect women's experience of the drawbacks of screening and increased concern about ovarian cancer risk, as well as having opportunities to consider surgery as an alternative risk management strategy whilst using screening as an interim measure.

KW - Ovarian cancer

KW - Ovarian cancer screening

KW - Familial cancer

KW - Withdrawal from screening

KW - Cancer-specific distress

KW - Risk-reducing salpingo-oophorectomy

U2 - 10.1016/j.ygyno.2011.09.015

DO - 10.1016/j.ygyno.2011.09.015

M3 - Article

SN - 0090-8258

VL - 124

SP - 158

EP - 163

JO - Gynaecologic Oncology

JF - Gynaecologic Oncology

IS - 1

ER -